Read More

FDA Refuses Neurology-Focused Clene’s Accelerated Approval For Amyotrophic Lateral Sclerosis Treatment, Shares Fall

Clene Inc (NASDAQ: CLNN) provided an amyotrophic lateral sclerosis (ALS) regulatory update from its recent meeting with the FDA to discuss CNM-Au8 for ALS, presenting initial clinical and Neurofilament Light Chain (NfL) biomarker results from the completed 

CLNN